California’s Gynesonics reported raising $3 million in a new debt offering as it pursues development of its VizAblate fibroid treatment device.
Gynecological
Bioness launches clinical trial for StimRouter in overactive bladder
Bioness last week said it’s making progress with a Canadian study of its StimRouter neuromodulation device designed to expand the number of conditions for which it can be used for treatment.
UnitedHealth tightens hysterectomy coverage
FDA approves Pelvalon’s fecal incontinence device
HCA hospitals halt use of uterine fibroid surgical tool
(Reuters) — HCA Holdings (NYSE:HCA), the largest for-profit U.S. hospital operator, said a procedure for removing uterine fibroids that’s been linked to the spread of cancer will no longer be performed at its facilities.
Plaintiffs in Bard’s pelvic mesh MDL want cases tried together
FDA adds ‘black box’ warning to power morcellator labels
First U.S. patients treated with Boston Scientific’s Symphion fibroid device
Defense opens in Boston Scientific pelvic mesh trial
Boston Scientific faces federal mesh trials today
Gynesonics wins FDA nod for VizAblate pilot trial
Gynesonics said it won an FDA investigational device exemption for its VizAblate system with an outpatient option for treating symptomatic uterine fibroids.